| Name | CABOTEGRAVIR SODIUM |
|---|---|
| Synonyms |
(3S,11-N-(2,4-DIFLUOROBENZYL)-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11A-HEXAHYDROOXAZOLO[3,2-A]PYRIDO[1,2-D]PYRAZINE-8-CBOXAMIDE, SODIUM SALT
Sodium (3S,11-8-((2,4-difluorobenzyl)cbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate S-265744B GSK1265744 (sodiuM salt) ISO 9001:2015 REACH 3L12PT535M Sodium (3S,11aR)-8-[(2,4-difluorobenzyl)carbamoyl]-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate GSK1265744B GSK1265744 (GSK744) Sodium salt Sodium Caboteavir Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, sodium salt, (3S,11aR)- (1:1) GSK1265744 (sodiuM salt) Caboteavir Sodium |
| Description | Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral drugs (ARVs)[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 2.5 nM (HIVADA)[1] |
| References |
| Molecular Formula | C19H16F2N3NaO5 |
|---|---|
| Molecular Weight | 427.334 |
| Exact Mass | 427.095581 |